New Study for ANGO's NanoKnife - Analyst Blog

By
A A A

AngioDynamics Inc. ( ANGO ) has enrolled the first patient in a multi-center study evaluating the efficiency of the NanoKnife System for ablation of prostrate cancer. The clinical trial is being conducted by the Clinical Research Office of the Endourological Society (CROES) at the Academic Medical Center in Amsterdam.

"The Safety and Efficacy of Irreversible Electroporation (IRE) for the Ablation of Prostate Cancer Assessed by Procedural Related Side Effects and Post Prostatectomy Histology: A Prospective Human In-Vivo Study" intends to evaluate the safety, efficacy and patient satisfaction of AngioDynamics' flagship NanoKnife offering in treating prostrate cancer. The study will enroll 16 eligible patients who will be treated with the NanoKnife System roughly a month before prostatectomy. On successful completion of this study, CROES will conduct a second study with 200 patients.

Researchers in the urology field have been increasingly analyzing the effectiveness of focal ablation for the treatment of low-risk prostrate cancer in a minimally invasive manner. We are encouraged by AngioDynamics' efforts to invest in clinical trials to analyze the potential of the NanoKnife System. The company has invested $26.3 million on research & development (R&D) in fiscal 2013.

The N.Y.-based therapeutic and diagnostic devices maker is conducting similar studies in the U.S. where institutes such as the University of Miami have shown interest in conducting a study on the NanoKnife upon approval from the Institutional Review Board (IRB). Moreover, the U.S. FDA has also cleared an Investigational Device Exemption (IDE) recently to begin a clinical trial of the product for the ablation of focal prostate cancer. The company plans to start patient enrollment in the second quarter of fiscal 2014, which ends on Nov 30, 2013.

AngioDynamics should continue to benefit from the ongoing shift from open surgery to less invasive interventional procedures. Despite the near-term operational glitches, the company has the ability to grow in the long term on the back of higher international sales, new products, acquisitions, as well as operational synergies from its cost saving measures.

ANGO has a Zacks Rank #3 (Hold). Medical stocks such as Cyberonics ( CYBX ), Given Imaging ( GIVN ) and Luminex ( LMNX ) are worth considering. All these stocks have a Zacks Rank #2 (Buy).



ANGIODYNAMICS (ANGO): Free Stock Analysis Report

CYBERONICS INC (CYBX): Free Stock Analysis Report

GIVEN IMAGING (GIVN): Get Free Report

LUMINEX CORP (LMNX): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ANGO , CYBX , GIVN , IDE , IRE

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

183,639,073
  • $42.32 ▲ 3.85%
82,623,623
  • $15.99 ▼ 22.79%
39,547,942
  • $119 ▲ 1.19%
32,107,751
  • $77.62 ▲ 2.63%
29,684,848
  • $10.60 ▲ 2.02%
27,615,309
  • $24.03 ▲ 0.38%
26,917,669
  • $31.10 ▲ 2.07%
26,464,306
  • $47.75 ▲ 0.59%
As of 11/26/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com